A consent decree and a $100 million investment to upgrade its key OTC plant have not led Johnson & Johnson to give up on its Fort Washington, PA, operations, CEO Alex Gorsky told investors today.
Johnson & Johnson paid a pretty penny for orthopedics giant Synthes, but last year's $21.3 billion acquisition made quite a mark on the company's annual report, as J&J posted 6.4% revenue growth in its devices division and a 34.3% jump in its ortho business.
The FDA is looking to rework its guidance on all-metal hip implants, proposing a rule change that would require devicemakers to demonstrate the safety and effectiveness of their devices before they're allowed to keep selling them.
Johnson & Johnson's new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators.
Johnson & Johnson, whose McNeil Consumer Healthcare is operating under an FDA consent decree, is taking a sales hit this flu season as consumers go to some pharmacies and find few or no Tylenol products on the shelves.
CVS, the drugstore chain, will stop stocking Tylenol in some of its stores. Ongoing supply problems have store shelves still empty, and CVS wants to fill those holes.
Any discussion on the near-term future of Big Pharma starts with a review of the top drugs in Phase III. And this year's crop includes a collection of some high-flying blockbuster prospects that has analysts encouraged enough to allow that the productivity gains seen over the last two years could translate into some big new approvals in 2013.
Last week, Johnson & Johnson got hit with another suit over its now-recalled ASR hip implant. Now, the company and its DePuy subsidiary face litigation over their other hip device, the Pinnacle.
FiercePharma Editor Tracy Staton took a dive into the world of "open" collaboration in the drug business, and how a spate of efforts among drugmakers to join forces on a range of research woes has captivated the industry. The big question is, will these efforts work? Download
Johnson & Johnson nabbed an FDA committee's support for its new diabetes drug, canaglifozin, now dubbed Invokana. That's good for J&J, of course. It's not so good for Merck, whose Januvia franchise would be directly in Invokana's sights.